Light Mode
$285.64 ↑ +0.00 (+0.00%) Trading Up from the previous close of $285.64, $1.13 below the day’s high of $286.77
+86.93 (+43.75%) / 6M
Momentum, market sentiment, and recent alerts
ABBV reads very good: price sits above both the 20- and 200-day averages, short interest is falling month over month, the 12-month move is +25.3%.
Earnings, valuation, and balance sheet
Company profile and competitor comparison
AbbVie, Inc. is a research-based biopharmaceutical company, which engages in the development and sale of pharmaceutical products. It focuses on treating conditions such as chronic autoimmune diseases in rheumatology, gastroenterology, and dermatology, oncology, including blood cancers, virology, including hepatitis C virus (HCV) and human immunodeficiency virus (HIV), neurological disorders such as Parkinson’s disease, metabolic disorders, including thyroid disease and complications associated with cystic fibrosis, pain associated with endometriosis, and other serious health conditions. The company was founded on October 19, 2011 and is headquartered in North Chicago, IL.
Real-time scanning and AI-generated signals across the entire market.
Prices and alerts are delayed by at least 20 minutes. Chart history reflects daily closing prices. Information is provided for research purposes only and is not investment advice.